GeneReach Financial Statements From 2010 to 2024
| 4171 Stock | TWD 28.90 0.20 0.70% |
Check GeneReach Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GeneReach Biotechnology's main balance sheet or income statement drivers, such as , as well as many indicators such as . GeneReach financial statements analysis is a perfect complement when working with GeneReach Biotechnology Valuation or Volatility modules.
GeneReach |
GeneReach Biotechnology Company Current Valuation Analysis
GeneReach Biotechnology's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current GeneReach Biotechnology Current Valuation | 2.09 B |
Most of GeneReach Biotechnology's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GeneReach Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, GeneReach Biotechnology has a Current Valuation of 2.09 B. This is 85.45% lower than that of the Healthcare sector and 55.02% lower than that of the Biotechnology industry. The current valuation for all Taiwan stocks is 87.43% higher than that of the company.
GeneReach Biotechnology Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining GeneReach Biotechnology's current stock value. Our valuation model uses many indicators to compare GeneReach Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across GeneReach Biotechnology competition to find correlations between indicators driving GeneReach Biotechnology's intrinsic value. More Info.GeneReach Biotechnology is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.44 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for GeneReach Biotechnology is roughly 2.28 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the GeneReach Biotechnology's earnings, one of the primary drivers of an investment's value.About GeneReach Biotechnology Financial Statements
GeneReach Biotechnology investors use historical fundamental indicators, such as GeneReach Biotechnology's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in GeneReach Biotechnology. Please read more on our technical analysis and fundamental analysis pages.
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. GeneReach Biotechnology Corp. was founded in 2004 and is headquartered in Taichung, Taiwan. GENEREACH BIOTECHNOLOGY operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange.
Pair Trading with GeneReach Biotechnology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if GeneReach Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GeneReach Biotechnology will appreciate offsetting losses from the drop in the long position's value.Moving together with GeneReach Stock
| 0.78 | 4743 | Oneness Biotech | PairCorr |
| 0.88 | 6547 | Medigen Vaccine Biologics | PairCorr |
| 0.91 | 4174 | OBI Pharma | PairCorr |
Moving against GeneReach Stock
| 0.89 | 2891 | CTBC Financial Holding | PairCorr |
| 0.89 | 2891B | CTBC Financial Holding | PairCorr |
| 0.84 | 2883 | China Development | PairCorr |
| 0.81 | 2330 | Taiwan Semiconductor | PairCorr |
| 0.78 | 0057 | Fubon MSCI Taiwan | PairCorr |
The ability to find closely correlated positions to GeneReach Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GeneReach Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GeneReach Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GeneReach Biotechnology to buy it.
The correlation of GeneReach Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GeneReach Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GeneReach Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GeneReach Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for GeneReach Stock Analysis
When running GeneReach Biotechnology's price analysis, check to measure GeneReach Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneReach Biotechnology is operating at the current time. Most of GeneReach Biotechnology's value examination focuses on studying past and present price action to predict the probability of GeneReach Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneReach Biotechnology's price. Additionally, you may evaluate how the addition of GeneReach Biotechnology to your portfolios can decrease your overall portfolio volatility.